United States: Life Sciences, Biotechnology & Nanotechnology

On 30 April 2026, the EU Commission published its draft revised EU merger guidelines (Guidelines) which could come into effect by the end of 2026. Whilst in draft form, the Guidelines reflect the direction of travel for the regime, and the Commission has already started to adopt an approach aligned with them.

ISO notes that in common with other nanostructured materials, the manufacturing and material specification of nanoporous silica microparticles are complex.

This comprehensive healthcare policy update examines Congress's return from recess with a focus on bipartisan healthcare legislation, including remote patient monitoring expansion, prior authorization reform, and ACA premium tax credit extensions. The analysis covers regulatory developments from CMS and FDA, including significant changes to hospital outpatient payment systems, 340B drug pricing policies, and the launch of Medicare's GLP-1 Bridge program.

Vertex Pharmaceuticals has secured FDA approval to expand CASGEVY's indication to children as young as two years old with sickle cell disease or transfusion-dependent beta thalassemia, making it the first CRISPR-based gene-editing therapy available for this younger patient population. The approval, reviewed under the FDA's Commissioner's National Priority Voucher pilot program, follows recent European data presentations demonstrating efficacy and safety in pediatric patients. This expansion allows clinician

The OECD has published a comprehensive policy paper examining how member countries are adapting their governance frameworks to support responsible innovation in synthetic biology. The analysis reviews national strategies, policy instruments, and governance initiatives across five key dimensions, revealing emerging practices while highlighting uneven implementation across jurisdictions. Drawing on examples from multiple countries, the paper identifies policy considerations for strengthening anticipatory gove

This digest covers key virtual and digital health regulatory and public policy developments during May and early June 2026 from the United States, United Kingdom, and European Union.

The U.S. Department of War has designated WuXi AppTec, a major contract development and manufacturing organization partnering with numerous U.S. biotechnology and pharmaceutical companies, as a "Chinese military company" under Section 1260H.

On June 4, 2026, Teva Pharmaceutical Industries Ltd. (“Teva”) announced the launch of its aflibercept biosimilar, AHZANTIVE®, in Europe.

Prior authorization has become one of the most frustrating parts of pharmacy operations. It delays care, burdens prescribers, confuses patients, and places pharmacies in the middle of disputes they often did not create.